4564.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 02:38):

Stats
Dagens volum	2.65M
Gjennomsnittsvolum	2.43M
Markedsverdi	3.70B
EPS	¥0 ( 2024-02-08 )
Neste inntjeningsdato	( ¥0 ) 2024-05-09
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-2.96
ATR14	¥0.485 (2.85%)

Volum Korrelasjon

Lang: 0.04 (neutral)

Kort: 0.59 (weak)

Signal:(46.29) Neutral

OncoTherapy Science, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

OncoTherapy Science, Inc. Korrelasjon - Valuta/Råvare

-0.33
( neutral )

0.18
( neutral )

0.51
( weak )

0.16
( neutral )

-0.03
( neutral )

0.22
( neutral )

OncoTherapy Science, Inc. Økonomi

Annual	2022
Omsetning:	¥1.13B
Bruttogevinst:	¥41.69M (3.67 %)
EPS:	¥-5.81

FY	2022
Omsetning:	¥1.13B
Bruttogevinst:	¥41.69M (3.67 %)
EPS:	¥-5.81

FY	2022
Omsetning:	¥1.15B
Bruttogevinst:	¥113.91M (9.87 %)
EPS:	¥-13.72

FY	2021
Omsetning:	¥332.48M
Bruttogevinst:	¥19.54M (5.88 %)
EPS:	¥-8.86

Financial Reports:

No articles found.

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.